FDA
-
-
-
-
-
-
-
Can-Fite Provides Update on Clinical and Financial Status
-
-
-
-
-
-
-
Can-Fite BioPharma (CANF) Announces $3.0 Million Registered Direct Offering of American Depositary Shares
-
-
-
-
-
-
-
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
-
-
-
-
-
-
-
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
-
-
-
-
-
-
-
Can-Fite BioPharma (CANF): Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
-
-
-
-
-
-
-
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
-
-
-
-
-
-
-
Can-Fite Bio (CANF) Announces Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

